Cargando…

Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma

BACKGROUND: Transarterial chemoembolization (TACE) is an effective treatment for primary hepatocellular carcinoma (PHC). Radioactive iodine therapy has been used in the treatment of advanced PHC, especially in patients with portal vein tumor thrombosis. However, data on the therapeutic effect of TAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Huang, Kun, Zhang, Yu, Wu, Yi-Fan, Yue, Zhen-Dong, Fan, Zhen-Hua, Liu, Fu-Quan, Li, Yong-Wu, Dong, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896495/
https://www.ncbi.nlm.nih.gov/pubmed/36741065
http://dx.doi.org/10.4240/wjgs.v15.i1.105
_version_ 1784882063486222336
author Wang, Lei
Huang, Kun
Zhang, Yu
Wu, Yi-Fan
Yue, Zhen-Dong
Fan, Zhen-Hua
Liu, Fu-Quan
Li, Yong-Wu
Dong, Jian
author_facet Wang, Lei
Huang, Kun
Zhang, Yu
Wu, Yi-Fan
Yue, Zhen-Dong
Fan, Zhen-Hua
Liu, Fu-Quan
Li, Yong-Wu
Dong, Jian
author_sort Wang, Lei
collection PubMed
description BACKGROUND: Transarterial chemoembolization (TACE) is an effective treatment for primary hepatocellular carcinoma (PHC). Radioactive iodine therapy has been used in the treatment of advanced PHC, especially in patients with portal vein tumor thrombosis. However, data on the therapeutic effect of TACE combined with radioactive iodine therapy in PHC are scarce. AIM: To investigate the clinical efficacy of TACE combined with radioactive iodine implantation therapy in advanced PHC via perfusion computed tomography (CT). METHODS: For this study, 98 advanced PHC patients were recruited and divided randomly into the study and control groups. Patients in the study group were treated with TACE combined radioactive iodine implantation therapy. Patients in the control group were treated with only TACE. The tumor lesion length, clinical effect, serum alpha-fetoprotein (AFP) and CT perfusion parameters were compared before and after therapy, and statistical analysis was performed. RESULTS: There was no significant difference in tumor length and serum AFP between the study and control groups (P > 0.05) before treatment. However, the tumor length and serum AFP in the study group were lower than those in the control group 1 mo and 3 mo after therapy. After 3 mo of treatment, the complete and partial remission rate of the study group was 93.88%, which was significantly higher than the control group (77.55%) (P < 0.05). Before treatment, there were no significant differences between the two groups on the perfusion CT variables, including the lesion blood volume, permeability surface, blood flow, hepatic artery flow and mean transit time (P > 0.05). After 3 mo of treatment, all perfusion CT variables were lower in the study group compared to the control group (P < 0.05). The survival time of patients in the study group was 22 mo compared to 18 mo in the control group, which was significantly different [log rank (Mantel-Cox) = 4.318, P = 0.038]. CONCLUSION: TACE combined with radioactive iodine implantation in the treatment of advanced PHC can inhibit the formation of blood vessels in tumor tissue and reduce the perfusion level of tumor lesions, thereby improving the clinical efficacy and prolonging the survival time of patients.
format Online
Article
Text
id pubmed-9896495
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-98964952023-02-04 Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma Wang, Lei Huang, Kun Zhang, Yu Wu, Yi-Fan Yue, Zhen-Dong Fan, Zhen-Hua Liu, Fu-Quan Li, Yong-Wu Dong, Jian World J Gastrointest Surg Clinical Trials Study BACKGROUND: Transarterial chemoembolization (TACE) is an effective treatment for primary hepatocellular carcinoma (PHC). Radioactive iodine therapy has been used in the treatment of advanced PHC, especially in patients with portal vein tumor thrombosis. However, data on the therapeutic effect of TACE combined with radioactive iodine therapy in PHC are scarce. AIM: To investigate the clinical efficacy of TACE combined with radioactive iodine implantation therapy in advanced PHC via perfusion computed tomography (CT). METHODS: For this study, 98 advanced PHC patients were recruited and divided randomly into the study and control groups. Patients in the study group were treated with TACE combined radioactive iodine implantation therapy. Patients in the control group were treated with only TACE. The tumor lesion length, clinical effect, serum alpha-fetoprotein (AFP) and CT perfusion parameters were compared before and after therapy, and statistical analysis was performed. RESULTS: There was no significant difference in tumor length and serum AFP between the study and control groups (P > 0.05) before treatment. However, the tumor length and serum AFP in the study group were lower than those in the control group 1 mo and 3 mo after therapy. After 3 mo of treatment, the complete and partial remission rate of the study group was 93.88%, which was significantly higher than the control group (77.55%) (P < 0.05). Before treatment, there were no significant differences between the two groups on the perfusion CT variables, including the lesion blood volume, permeability surface, blood flow, hepatic artery flow and mean transit time (P > 0.05). After 3 mo of treatment, all perfusion CT variables were lower in the study group compared to the control group (P < 0.05). The survival time of patients in the study group was 22 mo compared to 18 mo in the control group, which was significantly different [log rank (Mantel-Cox) = 4.318, P = 0.038]. CONCLUSION: TACE combined with radioactive iodine implantation in the treatment of advanced PHC can inhibit the formation of blood vessels in tumor tissue and reduce the perfusion level of tumor lesions, thereby improving the clinical efficacy and prolonging the survival time of patients. Baishideng Publishing Group Inc 2023-01-27 2023-01-27 /pmc/articles/PMC9896495/ /pubmed/36741065 http://dx.doi.org/10.4240/wjgs.v15.i1.105 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Clinical Trials Study
Wang, Lei
Huang, Kun
Zhang, Yu
Wu, Yi-Fan
Yue, Zhen-Dong
Fan, Zhen-Hua
Liu, Fu-Quan
Li, Yong-Wu
Dong, Jian
Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title_full Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title_fullStr Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title_full_unstemmed Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title_short Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
title_sort short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma
topic Clinical Trials Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896495/
https://www.ncbi.nlm.nih.gov/pubmed/36741065
http://dx.doi.org/10.4240/wjgs.v15.i1.105
work_keys_str_mv AT wanglei shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT huangkun shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT zhangyu shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT wuyifan shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT yuezhendong shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT fanzhenhua shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT liufuquan shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT liyongwu shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma
AT dongjian shorttermefficacyassessmentoftransarterialchemoembolizationcombinedwithradioactiveiodinetherapyinprimaryhepatocellularcarcinoma